HomeNewsOpinionRBI COVID Package 2.0 | It’s not enough to assure banks to bear risks

RBI COVID Package 2.0 | It’s not enough to assure banks to bear risks

Second package is better targeted towards NBFCs and HFCs, but could prove insufficient to meet the credit demands of those who need it the most.

April 17, 2020 / 12:23 IST
Story continues below Advertisement
LIVE updates of the Reserve Bank of India (RBI)'s Monetary Policy Committee (MPC) decisions
LIVE updates of the Reserve Bank of India (RBI)'s Monetary Policy Committee (MPC) decisions

You can take a horse to water, but cannot make it drink, goes the hoary chestnut. The Reserve Bank of India can flood the banking system with liquidity but it cannot make banks on-lend these funds. After the last set of measures announced on March 27, banks have taken to parking as much as Rs 6.9 lakh crore at the central bank’s overnight borrowing window (through an operation known as reverse repo). Other measures such as lending funds to banks for the specified purpose for buying corporate bonds has worked, but only the big boys are beneficiaries. Non-banking financial companies, which extend credit in places where commercial banks can’t go or do not want to go, were mostly left out in the previous set of announcements.

So, the central bank announced another set of measures where it plans to inject more liquidity into the banking system, get banks to lend to the entities – typically small and midsize firms which need it the most---and also offer banks some relief in terms of classifying loans as non-performing. It is a step in the right direction, but given the disruption that COVID-19 is causing, does it go far enough?

Story continues below Advertisement

What has RBI done?

It has said that banks will be able to borrow Rs 50,000 crore (to start with) from the central bank for the express purpose of onlending it to small and mid-sized NBFCs and microfinance companies. It has given another Rs 50,000 crore to the likes of NABARD (National Bank for Agriculture and Rural Development), NHB (National Housing Bank) and SIDBI (Small Industries Development Bank of India) which again provide funding to companies that provide small business finance, housing finance and so on. Thus, RBI has tried to address the issue being faced by NBFCs and HFCs which faced difficulties in accessing funds.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show